phrykt

Serina Therapeutics, Inc. (SER): who owns it and who trades it

As of Nov 3, 2026, SER insiders reported 22 open-market sales worth $360K and 7 purchases worth $78K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Randall Moreadith (Chief Scientific Officer), with $360K.

Latest filing Nov 3, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, SER insiders reported $78K of open-market purchases and $360K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$78K
7 trades, 4 people
Sales, 12 months
$360K
22 trades, 1 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Jul 7, 2026
Filed Jul 9, 2026

Purchases and sales by month

$116K$116KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 7, 2026Stephen K. BrannanDirectorPurchase1,000$2.03$2KForm 4
Jun 12, 2026Karen J WilsonDirectorPurchase5,000$1.77$8.8KForm 4
Jun 11, 2026Karen J WilsonDirectorPurchase5,100$1.75$8.9KForm 4
May 22, 2026Jay VenkatesanDirectorPurchase589$1.78$1KForm 4
May 22, 2026Karen J WilsonDirectorPurchase10,000$1.93$19.3KForm 4
May 21, 2026Karen J WilsonDirectorPurchase10,000$1.77$17.7KForm 4
May 19, 2026Richard Peter MarshallDirectorPurchase12,183$1.65$20.1KForm 4
Mar 23, 2026Randall MoreadithChief Scientific OfficerSale plan6,500$2.86$18.6KForm 4
Mar 19, 2026Randall MoreadithChief Scientific OfficerSale plan39,000$2.50$97.5KForm 4
Feb 2, 2026Randall MoreadithChief Scientific OfficerSale plan6,500$3.03$19.7KForm 4
Jan 28, 2026Randall MoreadithChief Scientific OfficerSale plan6,500$3.57$23.2KForm 4
Jan 22, 2026Randall MoreadithChief Scientific OfficerSale plan2,500$2.95$7.4KForm 4
Jan 21, 2026Randall MoreadithChief Scientific OfficerSale plan2,000$3.00$6KForm 4
Jan 20, 2026Randall MoreadithChief Scientific OfficerSale plan2,000$3.07$6.1KForm 4
Jan 14, 2026Randall MoreadithChief Scientific OfficerSale plan1,084$2.50$2.7KForm 4
Jan 13, 2026Randall MoreadithChief Scientific OfficerSale plan5,416$2.50$13.5KForm 4
Jan 8, 2026Randall MoreadithChief Scientific OfficerSale plan13,000$2.69$35KForm 4
Dec 23, 2025Randall MoreadithChief Scientific OfficerSale plan4,100$2.60$10.7KForm 4
Dec 22, 2025Randall MoreadithChief Scientific OfficerSale plan5,673$2.67$15.1KForm 4
Dec 16, 2025Randall MoreadithChief Scientific OfficerSale plan3,227$2.96$9.6KForm 4
Dec 12, 2025Randall MoreadithChief Scientific OfficerSale plan1,700$3.26$5.5KForm 4
Dec 11, 2025Randall MoreadithChief Scientific OfficerSale plan3,555$3.24$11.5KForm 4
Dec 10, 2025Randall MoreadithChief Scientific OfficerSale plan645$3.35$2.2KForm 4
Dec 9, 2025Randall MoreadithChief Scientific OfficerSale plan600$3.31$2KForm 4
Dec 3, 2025Randall MoreadithChief Scientific OfficerSale plan5,000$3.52$17.6KForm 4
Dec 2, 2025Randall MoreadithChief Scientific OfficerSale plan1,500$3.91$5.9KForm 4
Nov 25, 2025Randall MoreadithChief Scientific OfficerSale plan5,965$3.90$23.3KForm 4
Nov 24, 2025Randall MoreadithChief Scientific OfficerSale plan535$3.94$2.1KForm 4
Nov 18, 2025Randall MoreadithChief Scientific OfficerSale plan6,500$3.75$24.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Randall MoreadithChief Scientific Officer–$360KMar 23, 2026
Karen J WilsonDirector$54.8K–Jun 12, 2026
Richard Peter MarshallDirector$20.1K–May 19, 2026
Stephen K. BrannanDirector$2K–Jul 7, 2026
Jay VenkatesanDirector$1K–May 22, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SER short interest

Low short interest. 0.2% of SER shares are sold short: about 1 share in 543. Over the last 12 reports the number of shares short went down 93%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 46,787 SER shares were sold short, 0.2% of the shares outstanding, up 6.6% from the report before. At the average daily volume of 58,085 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.18%May 15Oct 302.99%

Days to cover

1.0May 15Oct 309.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202646,7870.18%+7%58,0851.0
Oct 15, 202643,8700.17%-22%38,4921.1
Sep 30, 202656,6000.22%-53%121,0921.0
Sep 15, 2026119,3600.47%+70%82,8641.4
Aug 31, 202670,0940.28%-52%53,1721.3
Aug 14, 2026145,5480.57%-35%69,2052.1
Jul 31, 2026222,920–-22%26,0878.6
Jul 15, 2026284,546–-0%54,3945.2
Jun 30, 2026285,430–-26%82,5593.5
Jun 15, 2026383,983–+11%182,4662.1
May 29, 2026345,042–+7%91,9743.8
May 15, 2026646,1102.62%+10%79,4144.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Serina Therapeutics company events

Serina Therapeutics filed 14 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Oct 9, 2026.

  1. Oct 9, 2026RulesChanged its bylaws or articles. Filing
  2. Sep 9, 2026AnnouncementMade another announcement. Filing
  3. Aug 27, 2026AgreementSerina Therapeutics, Inc. entered into a Common Stock Purchase Agreement and a related Registration Rights Agreement, each dated as of August 21, 2026, with Roth Principal Investments, LLC. Filing
  4. Aug 13, 2026ResultsReleased financial results. Filing
  5. Jul 23, 2026LeadershipSerina Therapeutics, Inc., together with its subsidiary Serina Therapeutics (AL), Inc., entered into an Amended and Restated Employment Agreement with Steve Ledger, the Company’s Chief Executive Officer. Filing
  6. Jul 22, 2026LeadershipSerina Therapeutics, Inc. issued a press release announcing the appointment of Farrell Simon, Pharm. Filing
  7. Jun 24, 2026VoteReported shareholder vote results. Filing
  8. May 14, 2026ResultsReleased financial results. Filing
  9. Apr 21, 2026LeadershipSerina Therapeutics (AL), Inc. (the “ Serina (AL) ”), a wholly owned subsidiary of Serina Therapeutics, Inc., named Srini Tenjarla, Ph.D., its Chief Technology Officer. Filing
  10. Mar 25, 2026ResultsReleased financial results. Filing
  11. Mar 23, 2026LeadershipIn connection with the Purchase Agreement described in Item 1.01 above, effective upon the closing of the initial tranche of the private placement, Mr. Bailey, as a current member of the Company’s Board of Directors, was appointed as Co-Chairman of the Board, to serve alongside the current… Filing
  12. Jan 28, 2026AnnouncementThe Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease. Filing
  13. Jan 15, 2026ListingSerina Therapeutics, Inc. received a notification from The NYSE American LLC stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of… Filing
  14. Dec 10, 2025AnnouncementSerina Therapeutics, Inc. issued a press release providing a regulatory update on the Company's lead SER-252 program for advanced Parkinson's disease, announcing the submission of the Company’s complete response to the FDA’s clinical hold letter for SER-252, dated November 25, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Serina Therapeutics financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SER in the last 120 days.

FiledHolderFormStake
Nov 3, 2026Sio Capital Management, LLC13G/A7.9%
Nov 3, 2026Sio Capital Management, LLC13G/A7.9%

Questions about Serina Therapeutics, Inc. (SER) stock

Are SER insiders buying or selling?

In the last 12 months, SER insiders reported 7 open-market purchases worth $78K and 22 sales worth $360K. The latest trade was on Jul 7, 2026. See every trade.

What is the short interest in SER?

As of Oct 30, 2026, 46,787 SER shares were sold short, 0.2% of the shares outstanding, up 6.6% from the report before. At the average daily volume of 58,085 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.